The estimated Net Worth of Rachel Smith is at least $86.7 Mille dollars as of 22 December 2017. Rachel Smith owns over 20,748 units of Capricor Therapeutics Inc stock worth over $86,727 and over the last 8 years he sold CAPR stock worth over $0. In addition, he makes $0 as Vice President - Research & Development at Capricor Therapeutics Inc.
Rachel has made over 1 trades of the Capricor Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 20,748 units of CAPR stock worth $3,320 on 22 December 2017.
The largest trade he's ever made was exercising 20,748 units of Capricor Therapeutics Inc stock on 22 December 2017 worth over $3,320. On average, Rachel trades about 5,187 units every 0 days since 2016. As of 22 December 2017 he still owns at least 20,748 units of Capricor Therapeutics Inc stock.
You can see the complete history of Rachel Smith stock trades at the bottom of the page.
Dr. Rachel Smith, Ph.D., is Vice President - Research & Development of CAPRICOR THERAPEUTICS, INC.. Dr. Smith joined Capricor in 2008 and is a co-inventor of the CardiosphereTM technology that forms the core of Capricor’s product portfolio. She also published the seminal proof-of-concept paper demonstrating the clinical utility of the Cardiosphere-derived stem cells in models of heart disease. Her research expertise encompasses the areas of stem cell biology, cardiac physiology, electrophysiology, as well as cell and tissue engineering. In 2012, Dr. Smith was appointed Vice President of Research and Development of Capricor and is responsible for developing the company’s clinical trial protocols and managing its regulatory and research partner relationships. Dr. Smith obtained her Ph.D. in Biomedical Engineering from Johns Hopkins University under the advisement of Dr. Eduardo Marbán and with the support of a Whitaker Foundation Graduate Fellowship and a National Science Foundation Graduate Fellowship. She received her undergraduate degree in Biomedical Engineering, Magna Cum Laude, from Tulane University.
Rachel Smith is 36, he's been the Vice President - Research & Development of Capricor Therapeutics Inc since 2013. There are 15 older and 2 younger executives at Capricor Therapeutics Inc. The oldest executive at Capricor Therapeutics Inc is Louis Grasmick, 90, who is the Independent Director.
Rachel's mailing address filed with the SEC is C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS, CA, 90211.
Over the last 11 years, insiders at Capricor Therapeutics Inc have traded over $949,404,468 worth of Capricor Therapeutics Inc stock and bought 6,444,826 units worth $18,843,106 . The most active insiders traders include Sinai Medical Center Cedars, John Edward A.Edward St. Jo... e Gregory W Schafer. On average, Capricor Therapeutics Inc executives and independent directors trade stock every 58 days with the average trade being worth of $494,068. The most recent stock trade was executed by David B Musket on 7 August 2024, trading 34,000 units of CAPR stock currently worth $47,260.
capricor therapeutics, inc. (nasdaq: capr) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways. capricor’s lead candidate, cap-1002, is an “off-the-shelf” cardiac cell therapy that is currently in clinical development for the treatment of duchenne muscular dystrophy (dmd). cap-1002 consists of allogeneic cardiosphere-derived cells, or cdcs, a unique population of cells which include progenitor cells that have been shown to exert potent immunomodulatory activity, which alters the immune system’s activity to stimulate cellular regeneration. cdcs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 140 human subjects across several clinical trials. capricor has
Capricor Therapeutics Inc executives and other stock owners filed with the SEC include: